Biopharmaceutical company Immunic, Inc. has officially announced the appointment of Dr. Michael A. Panzara, M.D., M.P.H., who has extensive experience in the biopharmaceutical field, as Chief Medical Officer.

Dr. Panzara has extensive credentials in drug research and clinical development, and this appointment will strengthen Immunic's leadership team in the field of innovative therapy development. Dr. Panzara has led multiple major clinical projects and achieved significant results in therapeutic areas such as neuroscience and immunology. His addition is expected to accelerate the clinical advancement of Immunic’s pipeline drugs and inject new professional perspectives into the company's strategic planning. This personnel change demonstrates Immunic's determination to continuously enhance its R&D capabilities and advance the global development of its candidate drugs. The company stated that Dr. Panzara’s industry experience and scientific insight will provide vital support for the development of innovative therapies for autoimmune and inflammatory diseases.